Proxygen harnesses the cellular protein quality control system to develop therapies against cancer and other life-threatening diseases. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase where it is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete and selective elimi